GLP-1 Research Supply After the 2022–2024 Incretin Surge
PeptideLab Editorial
Zespół redakcyjny
RUO only. We summarize published market context for educators and institutional buyers. Not guidance for personal weight management or off-label drug use.
Clinical demand for GLP-1 receptor agonists outpaced GMP drug capacity in many regions from late 2022 through 2024. That gap did not create a license for consumer “DIY pharmacy” — but it did increase legitimate preclinical interest in reference-grade incretin tools.
What changed in research procurement
- Assay comparability became harder when informal suppliers shipped inconsistent potency.
- Patent-disclosed sequences (e.g. retatrutide, tirzepatide) flooded SPPS suppliers globally — without interchangeable pharmaceutical quality.
- Institutional compliance tightened around RUO labeling and human-use disclaimers.
What qualified labs actually need
- Documented identity per lot (HPLC + MS).
- Stable lyophilized presentation with validated cold chain where required.
- Clear scope — in-vitro and approved animal models, not patient substitutes.
How this differs from retail marketplaces
Domestic consumer platforms actively block INN search terms for prescription intermediates. Export-oriented B2B channels (chemical directories, qualified factories) are where documented research material is discussed — always with COA review, never with injection tutorials.
PeptideLab’s role
We supply RUO lyophilized retatrutide, tirzepatide, and semaglutide with analytics suitable for metabolic pathway work — see products and our resource center for procurement guides.